ClinicalTrials.gg

Program

romiplostim

Also written as “Romiplostim”, “AMG 531” and “GNR-069”.

Its studies are mostly in Purpura, Thrombocytopenic, Idiopathic · Anemia, Aplastic · Myelodysplastic Syndromes · Carcinoma, Non-Small-Cell Lung · Purpura, Thrombocytopenic, led by 5 companies.

Furthest: phase 4, since May 21, 200938 company-led studies, 4 open or runningNext primary completion: Mar 31, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen252 open or runningphase 4since May 21, 2009Jan 27, 2005Sep 14, 2029phase 3 · NCT07700238
Kyowa Kirin80 open or runningphase 3since Feb 22, 2007Mar 20, 2006none ahead
AO GENERIUM20 open or runningphase 3since Jan 21, 2022Jan 21, 2022none ahead
Geropharm21 open or runningphase 3since Jul 4, 2024Dec 7, 2022Mar 31, 2028phase 3 · NCT06497036
Qilu Pharmaceutical11 open or runningphase 3since Dec 23, 2025Dec 23, 2025Oct 2029phase 3 · NCT07345000

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 23 studies since Jan 27, 2005.

  1. May 9, 2016Phase 3 study in Anemia, AplasticKyowa Kirin · NCT02773290 · 46 enrolled · Japan, Korea, Republic of
  2. Aug 11, 2016Phase 3 study in Purpura, Thrombocytopenic, IdiopathicKyowa Kirin · NCT02868099 · 203 enrolled · China
  3. Aug 11, 2016Phase 2 study in Purpura, Thrombocytopenic, IdiopathicKyowa Kirin · NCT02868060 · 16 enrolled · China
  4. Oct 12, 20172 phase 3 studiesAmgen · NCT03362177, NCT03343847
  5. Apr 24, 2019Phase 3 study in Carcinoma, Non-Small-Cell LungAmgen · NCT03937154 · 145 enrolled · United States, Argentina, Brazil and more
  6. May 9, 2019Phase 3 study in Anemia, AplasticKyowa Kirin · NCT03957694 · 17 enrolled · Japan
  7. Sep 18, 2019Phase 3 study in Anemia, AplasticKyowa Kirin · NCT04095936 · 24 enrolled · Japan
  8. Jan 21, 2022AO GENERIUM's first study: phase 3 study in Purpura, Thrombocytopenic, IdiopathicNew to AO GENERIUMAO GENERIUM · NCT05220878 · 160 enrolled · Russian Federation
  9. Apr 5, 2022Phase 2 study in Anemia, AplasticAmgen · NCT05323617
  10. Aug 3, 2022Phase 3 study in Purpura, Thrombocytopenic, IdiopathicAO GENERIUM · NCT05492409 · 160 enrolled · Russian Federation
  11. Dec 7, 2022Geropharm's first study: phase 1 study in PharmacodynamicsNew to GeropharmGeropharm · NCT05652595 · 56 enrolled · Russian Federation
  12. Jul 4, 2024Phase 3 study in Drug EffectGeropharm · NCT06497036 · 160 enrolled · Russian Federation
  13. Dec 23, 2025Qilu Pharmaceutical's first study: phase 3 study in Treatment-naïve Severe Aplastic AnemiaNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT07345000 · 210 planned
  14. Jul 7, 2026Phase 3 study in Purpura, Thrombocytopenic, IdiopathicAmgen · NCT07700238 · 126 planned · United States

Ahead

  1. Mar 31, 2028Primary completion: phase 3 study in Drug EffectGeropharm · NCT06497036
  2. Sep 14, 2029Primary completion: phase 3 study in Purpura, Thrombocytopenic, IdiopathicAmgen · NCT07700238
  3. Oct 2029Primary completion: phase 3 study in Treatment-naïve Severe Aplastic AnemiaQilu Pharmaceutical · NCT07345000

TargetBeta

MPL →read by rule
“Thrombopoietin receptor agonist”ChEMBL 37, by rule

Other programs on MPL

ProgramCompanyFurthest phaseStudies
eltrombopagruleGlaxoSmithKlinephase 449
avatrombopagruleEisaiphase 425
hetrombopag olamineruleJiangsu HengRui Medicinephase 315

Studies

All 38 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07700238Purpura, Thrombocytopenic, Idiopathic · United States3RecruitingAmgenSep 14, 2029126
NCT07345000Treatment-naïve Severe Aplastic Anemia3Not yet recruitingQilu PharmaceuticalOct 2029210
NCT06497036Drug Effect · Russian Federation3Active, not recruitingGeropharmMar 31, 2028160
NCT05652595Pharmacodynamics · Russian Federation1UNKNOWNGeropharmJun 30, 202456
NCT05492409Purpura, Thrombocytopenic, Idiopathic · Russian Federation3CompletedAO GENERIUMApr 3, 2024160
NCT05323617Anemia, Aplastic2WithdrawnAmgenFeb 25, 20250
NCT05220878Purpura, Thrombocytopenic, Idiopathic · Russian Federation3CompletedAO GENERIUMAug 22, 2023160
NCT04095936Anemia, Aplastic · Japan3CompletedKyowa KirinOct 7, 202124
NCT03957694Anemia, Aplastic · Japan3CompletedKyowa KirinNov 5, 202017
NCT03937154Carcinoma, Non-Small-Cell Lung · United States, Argentina, Brazil and more3Active, not recruitingAmgenMar 10, 2026145
NCT03362177Gastrointestinal Neoplasms · United States, Argentina, Austria and more3CompletedAmgenJan 25, 2024165
NCT03343847Chemotherapy-induced Thrombocytopenia3WithdrawnAmgenJul 17, 20210
NCT02868099Purpura, Thrombocytopenic, Idiopathic · China3CompletedKyowa KirinFeb 2017203
NCT02868060Purpura, Thrombocytopenic, Idiopathic · China2CompletedKyowa KirinAug 201716
NCT02773290Anemia, Aplastic · Japan, Korea, Republic of3CompletedKyowa KirinNov 14, 201746
NCT02279173Purpura, Thrombocytopenic, Idiopathic · United States, Australia, Belgium and more3CompletedAmgenAug 30, 2018203
NCT02094417Anemia, Aplastic · Korea, Republic of2CompletedKyowa KirinApr 24, 201735
NCT01444417Purpura, Thrombocytopenic, Idiopathic · United States, Australia, Canada3CompletedAmgenFeb 201562
NCT01143038Purpura, Thrombocytopenic, Idiopathic · United States, Australia, Czechia and more2CompletedAmgenSep 20, 201375
NCT01071954Purpura, Thrombocytopenic, Idiopathic · United States, Australia, Canada and more3CompletedAmgenJan 12, 201766
NCT00907478Thrombocytopenia4CompletedAmgenJan 9, 2014169
NCT00614523Myelodysplastic Syndromes2CompletedAmgenMar 31, 2011250
NCT00515203Purpura, Thrombocytopenic, Idiopathic2CompletedAmgenMar 200922
NCT00508820Purpura, Thrombocytopenic, Idiopathic3CompletedAmgenJan 1, 2011407
NCT00472290Myelodysplastic Syndromes–CompletedAmgenJul 18, 201172
NCT00440037Purpura, Thrombocytopenic · Japan3CompletedKyowa KirinJul 201144
NCT00418665Myelodysplastic Syndromes2CompletedAmgenMar 200939
NCT00415532Purpura, Thrombocytopenic, Idiopathic3CompletedAmgenNov 7, 2008234
NCT00413283Lung Neoplasms · United States, Austria, Canada and more2CompletedAmgenDec 200863
NCT00321711Myelodysplastic Syndromes2CompletedAmgenOct 19, 200969
NCT00305435Purpura, Thrombocytopenic2CompletedKyowa KirinNov 200612
NCT00303472Thrombocytopenia2CompletedAmgenMay 200872
NCT00283439Hodgkin Disease2CompletedAmgenMay 200839
NCT00117143Purpura, Thrombocytopenic2CompletedAmgenJul 19, 200416
NCT00116688Thrombocytopenia3CompletedAmgenJan 2010313
NCT00111475Purpura, Thrombocytopenic, Idiopathic2CompletedAmgenJun 17, 200445
NCT00102336Thrombocytopenia3CompletedAmgenDec 1, 200662
NCT00102323Thrombocytopenia3CompletedAmgenSep 1, 200663

How it is read

Names in the registry

  • “Romiplostim”, 22 entries
  • “AMG 531”, 6 entries
  • “GNR-069”, 2 entries
  • “Romiplostim N01”, 1 entry
  • “GP404141”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.